Adlane Soudani is Global Asset Lead at IPSEN. Adlane has 20+ years of international leadership in the pharmaceutical industry with extensive experience in the rare disease space. Over the years, Adlane has led strategic initiatives across multiple therapeutic areas, global launches, asset development and general management across multiple geographies.
Understanding patient experiences, preferences, and behaviours is critical to developing treatments that truly meet patient needs. Yet in rare diseases, capturing and applying these insights remains difficult due to small, diverse populations, delayed diagnoses, a lack of standardized methods, and limited regulatory guidance.
This panel will explore how both qualitative, and semi-quantitative patient data can inform more effective, patient-centred decisions across the product lifecycle in the rare disease space. Experts will address key barriers, such as data integration, resource constraints, and methodological gaps, and share practical strategies and real-world examples to overcome them.
Join the panel and gain a clear view of what meaningful patient experience data look like and how they can drive clinical development strategies, as well as pre-launch and market success